Herantis Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema ®
Herantis Pharma Plc Company release, inside information, 2 March 2021 at 2:00 p.m. Eastern European Time Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that clinical trial results from its Phase II study investigating Herantis’ patented gene therapy Lymfactin®, for the treatment of Breast Cancer Related Lymphedema (BCRL), were inconclusive. Lymfactin® is a unique gene therapy that induces expression of VEGF-C, an endogenous protein that is responsible for